Učitavanje...
Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma
BACKGROUND & AIMS: Infigratinib is a pan‐FGFR (fibroblast growth factor receptor) inhibitor that has shown encouraging activity in FGFR‐dependent hepatocellular carcinoma (HCC) models. However, long‐term treatment results in the emergence of resistant colonies. We sought to understand the mechan...
Spremljeno u:
| Izdano u: | Liver Int |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7894323/ https://ncbi.nlm.nih.gov/pubmed/33179425 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.14728 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|